PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients

被引：0
|
作者：
P Lu
J Hsu
C Keane
S Fettner
J Wang
N Ruperto
O Harari
HI Brunner
F De Benedetti
机构：
[1] Nutley,Roche
[2] Roche,undefined
[3] PRINTO,undefined
[4] PRCSG,undefined
[5] IRCCS Ospedale Ped Bambino Gesú,undefined
来源：
Pediatric Rheumatology | / 11卷 / Suppl 2期
关键词：
Juvenile Idiopathic Arthritis; Tocilizumab; Polyarticular Juvenile Idiopathic Arthritis; Linear Clearance; Poppk Analysis;
D O I：
10.1186/1546-0096-11-S2-P171
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 26 条
  • [1] Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight
    Lu, Peng
    Hsu, Joy
    Keane, Caroline
    Fettner, Scott
    Wang, Jianmei
    Ruperto, Nicolino
    Harari, Olivier
    Brunner, Hermine
    De Benedetti, Fabrizio
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S222 - S223
  • [2] PReS-FINAL-2062: The need for conducting different rehabilitation complexes for patients with juvenile idiopathic arthritis (JIA)
    TA Shelepina
    IP Nikishina
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [3] PReS-FINAL-2170: Work disability in adult patients with juvenile idiopathic arthritis (JIA)
    C Goldenstein-Schainberg
    J Gordo
    R Krieger
    LE Paula
    N Aikawa
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [4] PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
    R Nicolai
    E Cortis
    L Ravà
    C Bracaglia
    M Pardeo
    A Insalaco
    PS Buonuomo
    F De Benedetti
    AE Tozzi
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [5] PReS-FINAL-2045: Mutational analysis of sialic acid acetylesterase (siae) in juvenile idiopathic arthritis (JIA)
    E Tsitsami
    E Sevdali
    M Speletas
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [6] PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
    F Perfetti
    F Gesualdo
    V Messia
    A Insalaco
    C Bracaglia
    M Pardeo
    R Nicolai
    L Meli
    F De Benedetti
    S Magni Manzoni
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [7] PReS-FINAL-2020: Cell type specific transcriptome analysis in patients with enthesitis related arthritis category of juvenile idiopathic arthritis (JIA-ERA)
    A Aggarwal
    A Myles
    P Gaur
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [8] PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
    F De Benedetti
    HI Brunner
    E Baildam
    R Burgos-Vargas
    G Horneff
    HI Huppertz
    K Minden
    BL Myones
    K Onel
    J Wang
    K Bharucha
    D Lovell
    A Martini
    N Ruperto
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [9] PReS-FINAL-2112: Mapping the treatment effect of infliximab on a case of refractory anterior uveitis related to juvenile idiopathic arthritis (JIA)
    V Miranda
    C Zilhão
    P Menéres
    M Guedes
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [10] PReS-FINAL-2067: How does the self-experienced HRQOL work for children with JIA - juvenile idiopathic arthritis in Stockholm?
    K Berggren
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
123